Literature DB >> 18505179

Cytokine profiling in abacavir hypersensitivity patients.

Coral-Ann M Almeida1, Annalise M Martin, David Nolan, Andrew Lucas, Paul U Cameron, Ian James, Elizabeth Phillips, Simon Mallal.   

Abstract

BACKGROUND: Abacavir hypersensitivity in genetically susceptible individuals implicates an abacavir-specific T-cell response to either the parent drug or a metabolite generated in vivo. We have analysed the cytokine profile in antigen-presenting cells and the T-lymphocytes that are involved in the pathological immune response to abacavir.
METHODS: In this study, we compared abacavir-specific cytokine responses in cultured peripheral blood mononuclear cells (PBMCs) from HIV-infected abacavir hypersensitive, tolerant and naive individuals. Cells were cultured in the presence or absence of abacavir. Cytokine expression was determined by microarray analysis, enzyme-linked immunosorbent assays and flow cytometry.
RESULTS: We demonstrated using in vitro models of immune activation that the production of interferon-gamma was specifically induced by abacavir treatment in PBMCs obtained from hypersensitive patients carrying the HLA-B*5701 allele (median 123.86 compared with -30.83 for tolerant controls, P=0.001).
CONCLUSION: These results provide further insight into the immunological and metabolic basis of abacavir hypersensitivity syndrome. In vitro assays could assist in the identification of susceptible loci by providing a surrogate marker for the hypersensitivity reaction. Such a marker could be studied in unexposed individuals to shed further light on the immunopathogenesis of the abacavir hypersensitivity syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505179

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  9 in total

Review 1.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

Review 2.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

Review 3.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

Review 4.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

Review 5.  Successful translation of pharmacogenetics into the clinic: the abacavir example.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 6.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 7.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

8.  In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers.

Authors:  Ana Alfirevic; Faviel Gonzalez-Galarza; Catherine Bell; Klara Martinsson; Vivien Platt; Giovanna Bretland; Jane Evely; Maike Lichtenfels; Karin Cederbrant; Neil French; Dean Naisbitt; B Kevin Park; Andrew R Jones; Munir Pirmohamed
Journal:  Genome Med       Date:  2012-06-25       Impact factor: 11.117

Review 9.  Pharmacogenetics of drug hypersensitivity.

Authors:  Elizabeth J Phillips; Simon A Mallal
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.